Translational Medicine Individualizes Healthcare Discovery, Development and Delivery

Terzic, André

doi:10.2217/bmm.13.1

Cited by 4 publications

(5 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Aberrant expression of miRNAs is linked to numerous human diseases, including cancer, cardiovascular disease, neurodegenerative disease and obesity ( 7 – 10 ). Importantly, the discovery of stable miRNAs in readily accessible human biological fluids such as blood and urine has increased the potential utility of miRNAs as practical biomarkers for these diseases ( 11 – 25 ).…”

Section: Introductionmentioning

confidence: 99%

Blocking of targeted microRNAs from next-generation sequencing libraries

et al. 2015

View full text Add to dashboard Cite

Highly abundant microRNAs (miRNAs) in small RNA sequencing libraries make it difficult to obtain efficient measurements of more lowly expressed species. We present a new method that allows for the selective blocking of specific, abundant miRNAs during preparation of sequencing libraries. This technique is specific with little off-target effects and has no impact on the reproducibility of the measurement of non-targeted species. In human plasma samples, we demonstrate that blocking of highly abundant hsa-miR-16–5p leads to improved detection of lowly expressed miRNAs and more precise measurement of differential expression overall. Furthermore, we establish the ability to target a second abundant miRNA and to multiplex the blocking of two miRNAs simultaneously. For small RNA sequencing, this technique could fill a similar role as do ribosomal or globin removal technologies in messenger RNA sequencing.

show abstract

Section: Introductionmentioning

confidence: 99%

Blocking of targeted microRNAs from next-generation sequencing libraries

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Personalized medicine is having a transformative impact on disease risk assessment, prediction, prevention, prognosis, and cure 9 , 11 . The present discussion highlights the operational flow of technology along a supply chain of innovation, from laboratory to end users, which requires management at each individual step to maximize health‐care and economic benefits.…”

mentioning

confidence: 96%

“…What may be less appreciated is the complexity of processes leading from laboratory‐based discovery to individualized patient management algorithms in practice. We typically consider the science of translational therapeutics in discrete sequential steps in which the flow of information and technology moves from left to right along a continuum, from fundamental discovery of molecular principles and therapeutic targets to development involving clinical trials that prove efficacy and safety, through regulatory approval that certifies the utility of the management approach, to application in patients and populations—the “DDRU continuum.” 3 , 9 , 10 , 11 , 12 This model broadly categorizes the stages translating invention into practice. However, it obscures the integral contributions by individual practitioners and domain‐specific experts as well as the impact of the external environment, all of which shape the process at every phase, from discovery to application.…”

mentioning

confidence: 99%

Managing the Innovation Supply Chain to Maximize Personalized Medicine

Terzic

2014

Clin Pharmacol Ther

View full text Add to dashboard Cite

Personalized medicine epitomizes an evolving model of care tailored to the individual patient. This emerging paradigm harnesses radical technological advances to define each patient's molecular characteristics and decipher his or her unique pathophysiological processes. Translated into individualized algorithms, personalized medicine aims to predict, prevent, and cure disease without producing therapeutic adverse events. Although the transformative power of personalized medicine is generally recognized by physicians, patients, and payers, the complexity of translating discoveries into new modalities that transform health care is less appreciated. We often consider the flow of innovation and technology along a continuum of discovery, development, regulation, and application bridging the bench with the bedside. However, this process also can be viewed through a complementary prism, as a necessary supply chain of services and providers, each making essential contributions to the development of the final product to maximize value to consumers. Considering personalized medicine in this context of supply chain management highlights essential points of vulnerability and/or scalability that can ultimately constrain translation of the biological revolution or potentiate it into individualized diagnostics and therapeutics for optimized value creation and delivery. Clinical Pharmacology & Therapeutics (2014); 95 2, 113–118. doi:

show abstract

“…Familiar diagnostic biomarkers include traditional measurements (heart rate and blood pressure), imaging techniques (chest x-ray and mammograms) and protein measurements (PSA and CEA). The revolution in biology and high-throughput technology has provided an opportunity to develop a new generation of companion and complementary diagnostics, including single-nucleotide polymorphism analysis, genomic and proteomic profiling, epigenetic profiling and gene expression profiling [3]. In turn, these diagnostics increase disease-specific sensitivity and specificity, contributing to the accuracy of personalized disease management.…”

mentioning

confidence: 99%

Translational Medicine Individualizes Healthcare Discovery, Development and Delivery

Cited by 4 publications

References 25 publications

Blocking of targeted microRNAs from next-generation sequencing libraries

Blocking of targeted microRNAs from next-generation sequencing libraries

Managing the Innovation Supply Chain to Maximize Personalized Medicine

Companion Diagnostics at the Intersection of Personalized Medicine and Healthcare Delivery

Contact Info

Product

Resources

About